- Guide to PHARMACOLOGY
Synonyms: amivantamab-vmjw | JNJ-61186372 | JNJ-6372 | JNJ61186372 | Rybrevant®
amivantamab is an approved drug (FDA & EMA (2021))
Compound class: Antibody
Comment: Amivantamab (JNJ-61186372) is a bispecific monoclonal that targets EGFR and MET [1,3,6]. Examination of binding by surface plasmon resonance confirms that JNJ-61186372 can bind to EGFR and MET simultaneously . JNJ-61186372 binding inhibits phosphorylation of both of the target receptor tyrosine kinases in vitro. Tackling the tyrosine kinases from outside the cell is hypothesised to override the issue of treatment resistance due to kinase mutations that frequently arise during therapy with intracellulary-acting small molecule kinase inhibitors [2,4-5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA & EMA (2021))|
|International Nonproprietary Names|
|amivantamab-vmjw | JNJ-61186372 | JNJ-6372 | JNJ61186372 | Rybrevant®|
|GtoPdb PubChem SID||387065587|
|Search PubMed clinical trials||amivantamab|
|Search PubMed titles||amivantamab|
|Search PubMed titles/abstracts||amivantamab|